BioCentury
ARTICLE | Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin aims to tamp down neuron excitability with its conditionally active ion channels

March 27, 2020 1:39 AM UTC

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability.

4Bio Capital and Arkin Bio Ventures led the tranched round. New investor Takeda Ventures Inc. also participated, as did existing investors New York Ventures and Alexandria Venture Investments...

BCIQ Company Profiles

Redpin Therapeutics Inc.